Skadden is representing Pharmaceutical Product Development, Inc. in its $3.9 billion acquisition by The Carlyle Group and Hellman & Friedman, announced on October 3.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden is representing Pharmaceutical Product Development, Inc. in its $3.9 billion acquisition by The Carlyle Group and Hellman & Friedman, announced on October 3.